Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 29, 2016. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), and Connected Persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation plan activity.
- Transaction Type: Notional acquisition of Ordinary Shares and American Depositary Shares (ADSs) via dividend re-investment.
- Share Price (Ordinary): 1502.00 pence per share.
- Share Price (ADS): $42.64 per ADS.
- Dividend Date: April 14, 2016.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It details specific share acquisitions by the following individuals:
- Directors/PDMRs: Sir Andrew Witty, Dr M M Slaoui, Mr S Dingemans, Mr R G Connor, Mr N Hirons, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Mr D E Troy, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Connected Person: Dr K Slaoui (Connected to Dr M M Slaoui).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, or specific risk factors. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Plan holdings that vest following the end of the relevant measurement period. The transactions were notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Investor Verification Checklist
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares outstanding post-transaction to assess dilution impact, if any.
- Review the full dividend declaration details from April 14, 2016, to validate the re-investment price basis.
- Check subsequent filings for the actual vesting and payout of the notional dividends mentioned.